Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Metastatic Pheochromocytoma and Paraganglioma
NCT03008369Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- May 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in pheochromocytoma and Paraganglioma (PGL), sponsored by Mayo Clinic. Primary endpoint: Confirmed Tumor Response Rate up to 17 months. Started May 2017; status: completed.
02
Drugs
lenvatinib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT03008369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008369.